<DOC>
	<DOCNO>NCT01284335</DOCNO>
	<brief_summary>The purpose study determine safe dose LY573636-sodium use 5 separate combination approve cancer medication treat patient advanced cancer . Data study review side effect anti-tumor activity may associate LY573636-sodium combination treatment .</brief_summary>
	<brief_title>A Safety Study Patients With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>Patients histologically confirm solid malignancy lymphoma unresectable and/or metastatic monotherapy gemcitabine HCl , docetaxel , temozolomide , cisplatin , erlotinib would otherwise appropriate Must tumor progression receive standard/approved chemotherapy limited treatment option Must measurable nonmeasurable disease Have give write informed consent prior studyspecific procedure Must adequate hepatic , hematologic renal function Must discontinue previous therapy cancer , include chemotherapy , radiotherapy , cancerrelated hormonal therapy investigational therapy least 4 week ( 6 week mitomycinC nitrosoureas ) prior study enrollment recover acute effect therapy . Endocrine therapies treatment prostate cancer may continue , discretion investigator . Whole brain radiation must complete 90 day start study therapy . Patients without evidence brain metastasis receive prophylactic whole brain irradiation part standard care small cell lung cancer may include study short washout period pending approval Lilly physician . Males female reproductive potential must agree use medically approve contraceptive precaution trial 6 month follow last dose study drug . Females childbearing potential must negative serum pregnancy test within 7 day prior first dose study drug . Must serum albumin level great equal 3.0 g/dL ( 30 g/L ) . Must performance status 0 1 Eastern Cooperative Oncology Group ( ECOG ) scale Have receive treatment within 30 day initial dose study drug drug receive regulatory approval indication Have serious preexist medical condition opinion investigator would preclude participation study Patients active central nervous system brain metastasis time study entry . Patients sign symptom neurological compromise appropriate radiographic imaging perform study entry rule brain metastasis . Patients stable CNS metastasis require steroid may eligible . Have current hematologic malignancy ( lymphoma ) Patients serious concomitant disorder , include active bacterial , fungal , viral infection , incompatible study ) Patients actively receive warfarin ( CoumadinÂ® ) therapy Patients previously complete withdrawn study investigate LY573636 Patients know hypersensitivity one combination drug enrol treatment arm include chemotherapeutic combination Females pregnant breast feeding Have know positive test result HIV , hepatitis B , hepatitis C Patients receive amiodarone , quinidine , propofol , clozapine . Patients receive treatment strong moderate inhibitor CYP2C19 , include protonpump inhibitor ( PPIs ) . Esomeprazole pantoprazole allow administered 72 hour LY573636 administration .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Advanced solid tumor</keyword>
	<keyword>Unresectable</keyword>
	<keyword>Metastatic</keyword>
	<keyword>Limited treatment option</keyword>
	<keyword>Measurable nonmeasurable disease</keyword>
</DOC>